SCHEMBL23326195

SCHEMBL23326195

CCOC(=O)c1ccc(Nc2cnc3cc(NC(=O)Nc4ccc(F)c(Cl)c4)c(C)nc3n2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.51
▸ KMT2A Q03164 5/20 0.51
▸ CASP3 P42574 3/20 0.51
▸ SENP7 Q9BQF6 3/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.51
▸ NPC1 O15118 3/20 0.51
▸ RAB9A P51151 2/20 0.51
▸ ALDH1A1 P00352 1/20 0.51
▸ MAPT P10636 5/20 0.48
▸ TRPV1 Q8NER1 2/20 0.46
▸ LMNA P02545 2/20 0.44
▸ SLC2A1 P11166 1/20 0.44
▸ PIK3CA P42336 4/20 0.44
▸ MAPK8 P45983 4/20 0.44
▸ MAPK9 P45984 4/20 0.44
▸ MAPK10 P53779 4/20 0.44
▸ HTT P42858 1/20 0.41
▸ PDPK1 O15530 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ EGFR P00533 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20595298 0.89 PIK3CA (0.46) MEN1KMT2ACASP3SENP7SMN1; SMN2
SCHEMBL23326235 0.87 PIK3CA (0.54) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL20595308 0.86 MEN1 (0.48) MEN1KMT2ACASP3SENP7SMN1; SMN2
SCHEMBL23326251 0.85 MEN1 (0.52) MEN1KMT2ACASP3SENP7SMN1; SMN2
SCHEMBL23344437 0.83 PIK3CA (0.47) MEN1KMT2ACASP3SENP7SMN1; SMN2
SCHEMBL20595309 0.82 MEN1 (0.49) MEN1KMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL23344450 0.78 KCNQ3 (0.45) SMN1; SMN2NPC1RAB9APIK3CAMAPK8
SCHEMBL4922490 0.78 MAPT (0.76) MEN1KMT2ACASP3SENP7SMN1; SMN2
SCHEMBL20595300 0.77 MEN1 (0.64) MEN1KMT2ACASP3SENP7SMN1; SMN2
SCHEMBL23344463 0.76 MEN1 (0.55) MEN1KMT2ACASP3SENP7SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11117894-B2 Pyridopyrazine compounds and uses thereof CITY OF HOPE (US) 2021-09-14 — — US disclosed
US-11117894-B2 Pyridopyrazine compounds and uses thereof CITY OF HOPE (US) 2021-09-14 — — US disclosed
US-20210139476-A1 PYRIDOPYRAZINE COMPOUNDS AND USES THEREOF NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS (GR) 2021-05-13 — — US disclosed
US-20210139476-A1 PYRIDOPYRAZINE COMPOUNDS AND USES THEREOF NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS (GR) 2021-05-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11117894-B2 Pyridopyrazine compounds and uses thereof PDXK, DPYD, PNPO MEN1 4106/4885KMT2A 2474/4885CASP3 1577/4885
US-20210139476-A1 PYRIDOPYRAZINE COMPOUNDS AND USES THEREOF PDXK, DPYD, PNPO MEN1 4106/4885KMT2A 2474/4885CASP3 1577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback